Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Cancers
|
March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Filip Janku, Grace M Choong, Mateusz Opyrchal, et al.
British Journal of Cancer
|
April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Gabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 2, 2024
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, et al.
Gynecologic Oncology
|
June 1, 2021
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer
E Frangou, G Bertelli, S Love, et al.
Nucleic Acids Research
|
January 1, 2016
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer
Thomas G Hopkins, Manuela Mura, Hiba A Al-Ashtal, et al.
British Journal of Cancer
|
January 8, 2020
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement
Sarah P Blagden, Lucinda Billingham, Louise C Brown, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Trials
|
February 2, 2024
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol
Miriam Dixon-Zegeye, Rachel Shaw, Linda Collins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Cancers
|
March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Filip Janku, Grace M Choong, Mateusz Opyrchal, et al.
British Journal of Cancer
|
April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Gabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 2, 2024
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, et al.
Gynecologic Oncology
|
June 1, 2021
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer
E Frangou, G Bertelli, S Love, et al.
Nucleic Acids Research
|
January 1, 2016
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer
Thomas G Hopkins, Manuela Mura, Hiba A Al-Ashtal, et al.
British Journal of Cancer
|
January 8, 2020
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement
Sarah P Blagden, Lucinda Billingham, Louise C Brown, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Trials
|
February 2, 2024
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol
Miriam Dixon-Zegeye, Rachel Shaw, Linda Collins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
Page
of 6